How to Reconstitute Sermorelin: Step-by-Step Reconstitution Guide

What Is Sermorelin and Why Does Reconstitution Matter?

Sermorelin acetate is a 29-amino-acid synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) that stimulates the pituitary gland to secrete endogenous growth hormone. Because peptides are chemically unstable in aqueous solution, manufacturers supply Sermorelin as a freeze-dried (lyophilized) powder. Reconstitution converts that powder into an injectable solution, and doing it incorrectly can degrade the peptide, introduce contamination, or produce an inaccurate dose.

Sermorelin received FDA approval in 1997 under the brand name Geref for pediatric growth-hormone deficiency, giving it a formal regulatory history that many newer peptides lack. Today it is compounded by 503A and 503B pharmacies under USP standards. The USP General Chapter on injections sets sterility, particulate, and pH expectations that govern every step below.

Primary studies on GHRH analogue bioactivity confirm that even brief exposure to mechanical shear from vigorous mixing can cause aggregation of peptide chains, which reduces bioavailability and may trigger local injection-site reactions. That is the biochemical reason the reconstitution protocol below emphasizes slow, gentle mixing rather than speed.

How Sermorelin Works in the Body

Sermorelin binds the GHRH receptor on pituitary somatotroph cells, triggering a pulse of growth hormone (GH) release within 15 to 30 minutes of injection. Unlike recombinant human GH (rhGH), Sermorelin preserves the pituitary feedback axis, so GH output remains subject to normal somatostatin suppression. A 1996 study in the Journal of Clinical Endocrinology and Metabolism (N=47) found that nightly subcutaneous Sermorelin at 0.3 mg increased IGF-1 by a mean of 34% over 26 weeks in adults with partial GH deficiency, without suppressing endogenous pulsatile secretion.

Why Lyophilized Powder Requires Careful Handling

Lyophilization removes water under vacuum, leaving a fragile cake of peptide and excipients. The powder is hygroscopic, meaning it absorbs ambient moisture quickly once the vial seal is broken. USP Chapter 1, relating to injections and implanted drug products, mandates that reconstituted biologics be prepared under conditions that minimize particulate and microbial contamination. Working near a clean surface, avoiding breath contamination of open vials, and using sterile single-use needles each time are not optional courtesies; they are codified requirements.

Supplies You Need Before You Start

Gathering every item before you begin prevents mid-procedure contamination from opening drawers or cabinets after touching a needle. The list below is complete for a single reconstitution session.

Required Supplies

• Sermorelin lyophilized vial (typically 6 mg, from a licensed compounding pharmacy)
• Bacteriostatic water for injection, USP, 30 mL multi-dose vial
• Two U-100 insulin syringes: one 1 mL (for drawing BW) and one 0.3 mL or 1 mL (for dosing)
• Two alcohol swabs (70% isopropyl alcohol)
• One sterile 18 to 21 gauge drawing needle (optional, for transferring BW more easily)
• Sharps container
• Clean, flat surface wiped with 70% isopropyl alcohol

Why Bacteriostatic Water, Not Sterile Water

Bacteriostatic water contains 0.9% benzyl alcohol, a preservative that inhibits microbial growth across multiple draws from the same vial over 30 days. Sterile water for injection (SWFI) is preservative-free and is intended for single-use reconstitution only. The FDA Guidance on Bacteriostatic Water for Injection specifies that benzyl alcohol at 0.9% is an acceptable antimicrobial agent in multi-dose vials. Using SWFI with a peptide that will be drawn from repeatedly over weeks materially increases contamination risk.

Normal saline (0.9% sodium chloride) is sometimes suggested on forums. Saline is isotonic but lacks the bacteriostatic preservative and may affect peptide stability through ionic interactions. Unless a compounding pharmacist specifies saline for a particular formulation, bacteriostatic water is the standard diluent for Sermorelin.

Step-by-Step Reconstitution Protocol

Work through these eight steps in order. Do not skip steps, and do not rush the mixing phase.

Step 1: Wash Hands and Prepare the Surface

Wash hands for at least 20 seconds with soap and water. Dry with a clean paper towel. Wipe your work surface with a fresh 70% isopropyl alcohol swab and allow it to air-dry for 30 seconds. CDC hand-hygiene guidelines confirm that 20-second soap-and-water washing reduces microbial load on hands by 1 to 2 log units compared with a brief rinse, a reduction that matters when you subsequently touch non-sterile packaging.

Step 2: Inspect Both Vials

Check the Sermorelin vial. The powder should be white to off-white, forming a compact cake or loose powder. Discard the vial if the powder is discolored or if the vial seal is compromised.

Check the bacteriostatic water vial. The solution should be clear and colorless. If it appears cloudy or contains particles, discard it.

Step 3: Swab the Rubber Stoppers

Swab the rubber stopper of the Sermorelin vial and the rubber stopper of the bacteriostatic water vial, each with a separate alcohol swab. Allow each stopper to air-dry for 15 seconds. Inserting a needle before the alcohol evaporates can carry alcohol into the vial, which denatures peptide bonds. Research on benzyl alcohol and peptide stability confirms that even small alcohol concentrations alter the secondary structure of GHRH analogues under prolonged contact.

Step 4: Draw the Bacteriostatic Water

Using the 1 mL insulin syringe (or a separate drawing needle attached to a 3 mL syringe), draw the calculated volume of bacteriostatic water. For a 6 mg Sermorelin vial, the standard volume is 2 mL, producing a 3 mg/mL (3,000 mcg/mL) solution.

Pull the plunger back to your target volume. Verify the measurement by holding the syringe at eye level. Air bubbles in the barrel affect accuracy; flick the syringe and push bubbles out before proceeding.

Step 5: Inject BW Down the Vial Wall, Not Directly onto the Powder

Insert the needle through the center of the Sermorelin vial stopper at a 45-degree angle. Aim the needle tip so the stream of bacteriostatic water runs slowly down the inside glass wall of the vial, not directly onto the lyophilized cake. This matters because a direct stream physically disrupts the peptide matrix and causes foaming.

Depress the plunger slowly, over 10 to 15 seconds for a 2 mL volume. If you feel resistance, slightly reposition the needle; the stopper may have the bevel partially occluded.

Step 6: Gently Swirl, Never Shake

Remove the needle. Hold the vial between your palms and roll it slowly for 20 to 30 seconds, then swirl in a circular motion. The powder should dissolve completely within 60 seconds at room temperature. Studies on recombinant peptide formulations show that vortex mixing increases aggregate formation by up to 40% compared with gentle swirling, a finding that applies to GHRH analogues at comparable concentrations.

The reconstituted solution should be clear and colorless. A faint yellow tint or visible particulate means the peptide may have degraded; discard that vial.

Step 7: Label the Vial

Write the following on the vial or an adhesive label:

• Drug name and concentration (Sermorelin 3 mg/mL)
• Date of reconstitution
• Expiration date (30 days from today)
• Your initials

Unlabeled vials create serious medication errors if another household member encounters them.

Step 8: Refrigerate Immediately

Place the labeled vial in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Stability data for GHRH 1-29 analogues indicate that refrigerated aqueous solutions retain greater than 95% potency at 28 days, dropping to roughly 88% at 42 days. Thirty days is the conservative, clinically accepted window for compounded multi-dose peptide vials.

Sermorelin Dosing Calculator: Converting mcg to Insulin Units

This is the most common math error in peptide self-administration. Insulin syringes are calibrated in Units (U), not micrograms or milligrams. With a 3 mg/mL (3,000 mcg/mL) Sermorelin solution and a U-100 insulin syringe, each "unit" mark on the syringe equals 0.01 mL.

Formula:

Volume to draw (mL) = Desired dose (mcg) / Concentration (mcg/mL)

Then convert mL to Units: Units = Volume (mL) x 100

Worked examples at 3,000 mcg/mL:

| Desired Dose | Volume (mL) | U-100 Syringe Units | |---|---|---| | 100 mcg | 0.033 mL | ~3.3 units | | 150 mcg | 0.050 mL | 5 units | | 200 mcg | 0.067 mL | ~6.7 units | | 300 mcg | 0.100 mL | 10 units | | 500 mcg | 0.167 mL | ~16.7 units |

Doses of 100 to 300 mcg injected subcutaneously 5 nights per week are typical starting ranges in clinical practice for adults seeking GH optimization, based on dosing patterns referenced in endocrine literature on GHRH analogue protocols. Specific doses must be set by a prescribing clinician based on IGF-1 levels, body weight, and clinical goals.

How to Draw and Inject a Dose

Drawing the Dose

Remove the Sermorelin vial from the refrigerator 5 to 10 minutes before injection; cold solution is more viscous and harder to draw accurately. Swab the rubber stopper again with a fresh alcohol swab. Allow 15 seconds to dry.

Attach a fresh 29 to 31 gauge needle to your dosing syringe. Insert through the stopper, invert the vial, and draw slightly past your target volume. Then push back to the exact unit mark. This technique (draw-past-then-back) removes air from the barrel more reliably than drawing directly to the target. Pharmacist compounding guidelines note that accurate small-volume measurement with insulin syringes requires drawing past the target mark and returning to it, because plunger friction can cause over-draw.

Choosing the Injection Site

Subcutaneous injection sites for Sermorelin include:

• Abdomen (at least 2 inches from the navel)
• Lateral (outer) thigh
• Lateral hip

Rotate sites each injection. Using the same site repeatedly causes lipohypertrophy, a localized thickening of subcutaneous fat that reduces absorption. Clinical injection-technique guidelines from the American Diabetes Association recommend site rotation to prevent lipohypertrophy and maintain consistent drug absorption.

Injection Technique

Pinch a fold of skin with two fingers. Insert the needle at 45 to 90 degrees depending on the amount of subcutaneous tissue present; lean individuals should use 45 degrees. Inject slowly over 5 seconds. Withdraw the needle and apply light pressure with a clean swab; do not rub (rubbing disperses the peptide from the local depot before absorption).

Stability, Storage, and Signs of Degradation

Reconstituted Sermorelin stored at 2°C to 8°C remains stable for up to 30 days in most compounded formulations. Peptide stability studies show that GHRH analogues in bacteriostatic water maintain structural integrity at refrigerator temperatures significantly longer than at room temperature, where degradation accelerates within 48 hours.

Discard the vial immediately if you observe:

• Cloudiness or haze after the solution was previously clear
• Yellow, brown, or pink discoloration
• Visible flakes or threads
• Any odor from the solution
• The 30-day post-reconstitution date has passed

Do not return a used vial to the freezer. Freeze-thaw cycling of aqueous peptide solutions causes irreversible aggregation and loss of potency, as documented in formulation science literature examining GHRH analogue freeze-thaw stability.

Safety Considerations and Contraindications

Who Should Not Use Sermorelin

Sermorelin is contraindicated in individuals with active malignancy. Because GH stimulates IGF-1, which can act as a mitogen, prescribing guidelines caution against use in anyone with a personal or first-degree family history of pituitary tumors. The Endocrine Society's Clinical Practice Guideline on GH deficiency in adults states that GH-axis stimulation is contraindicated in active malignancy and in patients with evidence of intracranial neoplasia.

Pregnancy and lactation are contraindications due to insufficient safety data. Children under 18 should use Sermorelin only under direct pediatric endocrinology supervision.

Reported Side Effects

Clinical data from the Geref prescribing information and post-marketing surveillance include:

• Injection-site redness or swelling (most common, typically transient)
• Flushing within 30 minutes of injection
• Headache
• Nausea at higher doses
• Transient elevations in GH and IGF-1 beyond the reference range

A multicenter trial of Sermorelin in 121 adults found injection-site reactions in 17% of participants, all mild and resolving within 24 hours, with no serious adverse events attributed to the peptide itself.

Drug Interactions

Glucocorticoids blunt the GH response to Sermorelin by stimulating somatostatin release. Insulin, by lowering blood glucose, may transiently potentiate GH secretion and can confound IGF-1 monitoring. Thyroid hormone deficiency blunts GH axis responsiveness; clinicians typically optimize thyroid status before initiating Sermorelin. Evidence from endocrine physiology research confirms that glucocorticoid excess suppresses GHRH-stimulated GH secretion at the pituitary level.

Common Reconstitution Errors and How to Avoid Them

Error 1: Using Too Little or Too Much Bacteriostatic Water

Adding only 1 mL to a 6 mg vial creates a 6 mg/mL concentration. At that concentration, a 300 mcg dose requires only 5 units on a U-100 syringe, which is difficult to measure accurately with most syringes. Adding 4 mL creates 1.5 mg/mL; doses remain accurate but the vial volume is large relative to the dose, increasing the number of punctures needed per vial.

The 2 mL / 3 mg/mL standard balances dosing accuracy against vial economy. Your prescribing pharmacist may direct a different ratio; follow written dispensing instructions before using the table above.

Error 2: Shaking the Vial

Shaking introduces air-water interfaces that denature peptide chains through mechanical stress. Formulation research on growth-hormone-related peptides consistently identifies agitation as a primary cause of aggregate formation that reduces biological activity. Gentle swirling is the correct technique regardless of how slowly the powder dissolves.

Error 3: Not Rotating Needle Gauge for Drawing vs. Dosing

A 29 to 31 gauge needle appropriate for subcutaneous injection draws slowly from the vial. Using an 18 to 21 gauge drawing needle to transfer bacteriostatic water from its vial to the syringe, then switching to a fine gauge for injection, saves time and reduces rubber-coring of the stopper. This is standard compounding practice. USP General Chapter 1 on injections addresses needle gauge selection in the context of minimizing particulate generation from rubber closures.

Error 4: Injecting into Muscle Instead of Subcutaneous Tissue

Sermorelin is formulated for subcutaneous delivery. Intramuscular injection produces faster absorption and a sharper GH spike that may cause more pronounced side effects (flushing, headache) without improving efficacy. Lean individuals using a 90-degree angle and a 1/2-inch needle may inadvertently inject intramuscularly in the thigh; switching to a 45-degree angle or a 5/16-inch needle reduces that risk.

Error 5: Skipping the Injection-Site Rotation Log

A simple written log (date, site, dose) takes 10 seconds and prevents the site-overuse errors that accumulate silently over months. Many patients discover lipohypertrophy only when their IGF-1 response declines unexpectedly.

Monitoring After Starting Sermorelin

IGF-1 as the Primary Biomarker

IGF-1 (insulin-like growth factor 1) is the standard surrogate for GH axis activity. A baseline IGF-1 should be drawn before the first injection and repeated at 8 to 12 weeks after starting Sermorelin. The target range is typically age- and sex-adjusted mid-normal (roughly 100 to 250 ng/mL in adults aged 40 to 60, per Endocrine Society reference intervals).

Data from a 26-week controlled trial showed mean IGF-1 increases of 34% with nightly Sermorelin 0.3 mg vs. 4% with placebo (P<0.001, N=47), confirming that laboratory response is measurable within the first 2 to 3 months of therapy.

Fasting Blood Glucose

GH elevates fasting glucose transiently through counter-regulatory mechanisms. Patients with pre-diabetes or type 2 diabetes should monitor fasting glucose monthly and report sustained elevations above baseline to their prescribing clinician. The Endocrine Society notes that GH excess impairs insulin sensitivity, and even physiologic stimulation of GH secretion may warrant glucose monitoring in at-risk populations.

Thyroid Function

Low free T4 blunts the GH response to GHRH stimulation. A TSH and free T4 drawn at baseline identifies thyroid deficiency that should be corrected before attributing a poor IGF-1 response to Sermorelin non-response. Endocrine physiology research establishes that hypothyroidism reduces pituitary sensitivity to GHRH, partially through increased somatostatin tone.